Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.
Looking for a particular Immusoft employee's phone or email?
Immusoft Questions
The Immusoft annual revenue was $2 million in 2026.
Glen Grandea is the Vice President of Research of Immusoft.
15 people are employed at Immusoft.
Immusoft is based in Seattle, Washington.
The NAICS codes for Immusoft are [325, 325414, 54, 541, 32, 3254, 32541].
The SIC codes for Immusoft are [873, 87].
Top Immusoft Employees
-
Glen Grandea
Vice President of Research at Immusoft
Seattle, WA, US12 -
Jacob Wesley
Senior Vice President Medical Sciences at Immusoft
Rockville, MD, US25+ -
Alissa Kerner
SVP, Corporate Development at Immusoft
Boston, MA, US22 -
Robert Hayes
Chief Science Officer at Immusoft
Seattle, WA, US34 -
David Romenesko
Immusoft Board Member at Immusoft
Midland, MI, US34 -
Sean Ainsworth
CEO and Chairman at Immusoft
Ann Arbor, MI, US5+5+ -
Kevin Coleman
Associate Director Business Operations at Immusoft
San Diego, CA, US35+ -
Joell Solan
Director of Research and Development at Immusoft
Seattle, WA, US24 -
55+
-
Chris Hampe
Vice President of Research at Immusoft
Seattle, WA, US15
Related Companies
